Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 47

1.

Epigenetics in renal cell cancer: mechanisms and clinical applications.

Joosten SC, Smits KM, Aarts MJ, Melotte V, Koch A, Tjan-Heijnen VC, van Engeland M.

Nat Rev Urol. 2018 Jun 4. doi: 10.1038/s41585-018-0023-z. [Epub ahead of print] Review.

PMID:
29867106
2.

Author Correction: Analysis of DNA methylation in cancer: location revisited.

Koch A, Joosten SC, Feng Z, de Ruijter TC, Draht MX, Melotte V, Smits KM, Veeck J, Herman JG, Neste LV, Criekinge WV, de Meyer T, Engeland MV.

Nat Rev Clin Oncol. 2018 Apr 30. doi: 10.1038/s41571-018-0028-9. [Epub ahead of print]

PMID:
29713045
3.

Analysis of DNA methylation in cancer: location revisited.

Koch A, Joosten SC, Feng Z, de Ruijter TC, Draht MX, Melotte V, Smits KM, Veeck J, Herman JG, Neste LV, Criekinge WV, De Meyer T, Engeland MV.

Nat Rev Clin Oncol. 2018 Apr 17. doi: 10.1038/s41571-018-0004-4. [Epub ahead of print] Review. Erratum in: Nat Rev Clin Oncol. 2018 Apr 30;:.

PMID:
29666440
4.

Prognostic DNA methylation markers for sporadic colorectal cancer: a systematic review.

Draht MXG, Goudkade D, Koch A, Grabsch HI, Weijenberg MP, van Engeland M, Melotte V, Smits KM.

Clin Epigenetics. 2018 Mar 14;10:35. doi: 10.1186/s13148-018-0461-8. eCollection 2018. Review.

5.

Prognostic DNA methylation markers for renal cell carcinoma: a systematic review.

Joosten SC, Deckers IA, Aarts MJ, Hoeben A, van Roermund JG, Smits KM, Melotte V, van Engeland M, Tjan-Heijnen VC.

Epigenomics. 2017 Sep;9(9):1243-1257. doi: 10.2217/epi-2017-0040. Epub 2017 Aug 14. Review.

6.

PET imaging of zirconium-89 labelled cetuximab: A phase I trial in patients with head and neck and lung cancer.

van Loon J, Even AJG, Aerts HJWL, Öllers M, Hoebers F, van Elmpt W, Dubois L, Dingemans AC, Lalisang RI, Kempers P, Brans B, Winnepenninckx V, Speel EJ, Thunnissen E, Smits KM, Boellaard R, Vugts DJ, De Ruysscher D, Lambin P.

Radiother Oncol. 2017 Feb;122(2):267-273. doi: 10.1016/j.radonc.2016.11.020. Epub 2016 Dec 21.

PMID:
28012793
7.

A Four-Gene Promoter Methylation Marker Panel Consisting of GREM1, NEURL, LAD1, and NEFH Predicts Survival of Clear Cell Renal Cell Cancer Patients.

van Vlodrop IJH, Joosten SC, De Meyer T, Smits KM, Van Neste L, Melotte V, Baldewijns MMLL, Schouten LJ, van den Brandt PA, Jeschke J, Yi JM, Schuebel KE, Ahuja N, Herman JG, Aarts MJ, Bosman FT, Van Criekinge W, van Engeland M.

Clin Cancer Res. 2017 Apr 15;23(8):2006-2018. doi: 10.1158/1078-0432.CCR-16-1236. Epub 2016 Oct 18.

8.

Analysis of RET promoter CpG island methylation using methylation-specific PCR (MSP), pyrosequencing, and methylation-sensitive high-resolution melting (MS-HRM): impact on stage II colon cancer patient outcome.

Draht MX, Smits KM, Jooste V, Tournier B, Vervoort M, Ramaekers C, Chapusot C, Weijenberg MP, van Engeland M, Melotte V.

Clin Epigenetics. 2016 Apr 26;8:44. doi: 10.1186/s13148-016-0211-8. eCollection 2016.

9.

Production of Recombinant Chemokines and Validation of Refolding.

Veldkamp CT, Koplinski CA, Jensen DR, Peterson FC, Smits KM, Smith BL, Johnson SK, Lettieri C, Buchholz WG, Solheim JC, Volkman BF.

Methods Enzymol. 2016;570:539-65. doi: 10.1016/bs.mie.2015.09.031. Epub 2015 Nov 14.

10.

Decision support systems for personalized and participative radiation oncology.

Lambin P, Zindler J, Vanneste BG, De Voorde LV, Eekers D, Compter I, Panth KM, Peerlings J, Larue RT, Deist TM, Jochems A, Lustberg T, van Soest J, de Jong EE, Even AJ, Reymen B, Rekers N, van Gisbergen M, Roelofs E, Carvalho S, Leijenaar RT, Zegers CM, Jacobs M, van Timmeren J, Brouwers P, Lal JA, Dubois L, Yaromina A, Van Limbergen EJ, Berbee M, van Elmpt W, Oberije C, Ramaekers B, Dekker A, Boersma LJ, Hoebers F, Smits KM, Berlanga AJ, Walsh S.

Adv Drug Deliv Rev. 2017 Jan 15;109:131-153. doi: 10.1016/j.addr.2016.01.006. Epub 2016 Jan 14. Review.

PMID:
26774327
11.

Development and application of a screening model for evaluating bioenhanced dissolution in DNAPL source zones.

Phelan TJ, Abriola LM, Gibson JL, Smits KM, Christ JA.

J Contam Hydrol. 2015 Dec;183:1-15. doi: 10.1016/j.jconhyd.2015.10.001. Epub 2015 Oct 9.

PMID:
26484479
12.

Spectrin repeat containing nuclear envelope 1 and forkhead box protein E1 are promising markers for the detection of colorectal cancer in blood.

Melotte V, Yi JM, Lentjes MH, Smits KM, Van Neste L, Niessen HE, Wouters KA, Louwagie J, Schuebel KE, Herman JG, Baylin SB, van Criekinge W, Meijer GA, Ahuja N, van Engeland M.

Cancer Prev Res (Phila). 2015 Feb;8(2):157-64. doi: 10.1158/1940-6207.CAPR-14-0198. Epub 2014 Dec 23.

13.

Effect of NAPL Source Morphology on Mass Transfer in the Vadose Zone.

Petri BG, Fučík R, Illangasekare TH, Smits KM, Christ JA, Sakaki T, Sauck CC.

Ground Water. 2015 Sep-Oct;53(5):685-98. doi: 10.1111/gwat.12284. Epub 2014 Dec 23.

PMID:
25535651
14.

CHFR promoter methylation indicates poor prognosis in stage II microsatellite stable colorectal cancer.

Cleven AH, Derks S, Draht MX, Smits KM, Melotte V, Van Neste L, Tournier B, Jooste V, Chapusot C, Weijenberg MP, Herman JG, de Bruïne AP, van Engeland M.

Clin Cancer Res. 2014 Jun 15;20(12):3261-71. doi: 10.1158/1078-0432.CCR-12-3734.

15.

Epigenetics in radiotherapy: where are we heading?

Smits KM, Melotte V, Niessen HE, Dubois L, Oberije C, Troost EG, Starmans MH, Boutros PC, Vooijs M, van Engeland M, Lambin P.

Radiother Oncol. 2014 May;111(2):168-77. doi: 10.1016/j.radonc.2014.05.001. Epub 2014 May 23. Review.

PMID:
24861629
16.

Promoter CpG island methylation of RET predicts poor prognosis in stage II colorectal cancer patients.

Draht MX, Smits KM, Tournier B, Jooste V, Chapusot C, Carvalho B, Cleven AH, Derks S, Wouters KA, Belt EJ, Stockmann HB, Bril H, Weijenberg MP, van den Brandt PA, de Bruïne AP, Herman JG, Meijer GA, Piard F, Melotte V, van Engeland M.

Mol Oncol. 2014 May;8(3):679-88. doi: 10.1016/j.molonc.2014.01.011. Epub 2014 Feb 2.

17.

Emerging evidence for CHFR as a cancer biomarker: from tumor biology to precision medicine.

Derks S, Cleven AH, Melotte V, Smits KM, Brandes JC, Azad N, van Criekinge W, de Bruïne AP, Herman JG, van Engeland M.

Cancer Metastasis Rev. 2014 Mar;33(1):161-71. doi: 10.1007/s10555-013-9462-4. Review.

18.

A novel classification of colorectal tumors based on microsatellite instability, the CpG island methylator phenotype and chromosomal instability: implications for prognosis.

Simons CC, Hughes LA, Smits KM, Khalid-de Bakker CA, de Bruïne AP, Carvalho B, Meijer GA, Schouten LJ, van den Brandt PA, Weijenberg MP, van Engeland M.

Ann Oncol. 2013 Aug;24(8):2048-56. doi: 10.1093/annonc/mdt076. Epub 2013 Mar 26.

PMID:
23532114
19.

Promoter CpG island methylation markers in colorectal cancer: the road ahead.

Draht MX, Riedl RR, Niessen H, Carvalho B, Meijer GA, Herman JG, van Engeland M, Melotte V, Smits KM.

Epigenomics. 2012 Apr;4(2):179-94. doi: 10.2217/epi.12.9. Review.

PMID:
22449189
20.

The CpG island methylator phenotype in colorectal cancer: progress and problems.

Hughes LA, Khalid-de Bakker CA, Smits KM, van den Brandt PA, Jonkers D, Ahuja N, Herman JG, Weijenberg MP, van Engeland M.

Biochim Biophys Acta. 2012 Jan;1825(1):77-85. doi: 10.1016/j.bbcan.2011.10.005. Epub 2011 Oct 28. Review.

PMID:
22056543
21.

A let-7 microRNA SNP in the KRAS 3'UTR is prognostic in early-stage colorectal cancer.

Smits KM, Paranjape T, Nallur S, Wouters KA, Weijenberg MP, Schouten LJ, van den Brandt PA, Bosman FT, Weidhaas JB, van Engeland M.

Clin Cancer Res. 2011 Dec 15;17(24):7723-31. doi: 10.1158/1078-0432.CCR-11-0990. Epub 2011 Oct 12.

22.

Modified UroVysion scoring criteria increase the urothelial carcinoma detection rate in cases of equivocal urinary cytology.

Huysentruyt CJ, Baldewijns MM, Rüland AM, Tonk RJ, Vervoort PS, Smits KM, van de Beek C, Speel EJ.

Histopathology. 2011 Jun;58(7):1048-53. doi: 10.1111/j.1365-2559.2011.03859.x.

PMID:
21707706
23.

Genomic and epigenomic integration identifies a prognostic signature in colon cancer.

Yi JM, Dhir M, Van Neste L, Downing SR, Jeschke J, Glöckner SC, de Freitas Calmon M, Hooker CM, Funes JM, Boshoff C, Smits KM, van Engeland M, Weijenberg MP, Iacobuzio-Donahue CA, Herman JG, Schuebel KE, Baylin SB, Ahuja N.

Clin Cancer Res. 2011 Mar 15;17(6):1535-45. doi: 10.1158/1078-0432.CCR-10-2509. Epub 2011 Jan 28.

24.

Colorectal cancer epigenetics: complex simplicity.

van Engeland M, Derks S, Smits KM, Meijer GA, Herman JG.

J Clin Oncol. 2011 Apr 1;29(10):1382-91. doi: 10.1200/JCO.2010.28.2319. Epub 2011 Jan 10. Review.

PMID:
21220596
25.

Loss of SerpinA5 protein expression is associated with advanced-stage serous ovarian tumors.

Bijsmans IT, Smits KM, de Graeff P, Wisman GB, van der Zee AG, Slangen BF, de Bruïne AP, van Engeland M, Sieben NL, Van de Vijver KK.

Mod Pathol. 2011 Mar;24(3):463-70. doi: 10.1038/modpathol.2010.214. Epub 2010 Nov 19.

26.

Body mass index and von Hippel-Lindau gene mutations in clear-cell renal cancer: Results of the Netherlands Cohort Study on diet and cancer.

Smits KM, Schouten LJ, Hudak E, Verhage B, van Dijk BA, Hulsbergen-van de Kaa CA, Goldbohm RA, Oosterwijk E, van den Brandt PA.

Ann Epidemiol. 2010 May;20(5):401-4. doi: 10.1016/j.annepidem.2010.01.010.

PMID:
20382342
27.

Prognostic significance of Gremlin1 (GREM1) promoter CpG island hypermethylation in clear cell renal cell carcinoma.

van Vlodrop IJ, Baldewijns MM, Smits KM, Schouten LJ, van Neste L, van Criekinge W, van Poppel H, Lerut E, Schuebel KE, Ahuja N, Herman JG, de Bruïne AP, van Engeland M.

Am J Pathol. 2010 Feb;176(2):575-84. doi: 10.2353/ajpath.2010.090442. Epub 2009 Dec 30.

28.

Different angiogenic potential in low and high grade sporadic clear cell renal cell carcinoma is not related to alterations in the von Hippel-Lindau gene.

Baldewijns MM, van Vlodrop IJ, Smits KM, Vermeulen PB, Van den Eynden GG, Schot F, Roskams T, van Poppel H, van Engeland M, de Bruïne AP.

Cell Oncol. 2009;31(5):371-82. doi: 10.3233/CLO-2009-0482.

29.

N-Myc downstream-regulated gene 4 (NDRG4): a candidate tumor suppressor gene and potential biomarker for colorectal cancer.

Melotte V, Lentjes MH, van den Bosch SM, Hellebrekers DM, de Hoon JP, Wouters KA, Daenen KL, Partouns-Hendriks IE, Stessels F, Louwagie J, Smits KM, Weijenberg MP, Sanduleanu S, Khalid-de Bakker CA, Oort FA, Meijer GA, Jonkers DM, Herman JG, de Bruïne AP, van Engeland M.

J Natl Cancer Inst. 2009 Jul 1;101(13):916-27. doi: 10.1093/jnci/djp131. Epub 2009 Jun 17.

PMID:
19535783
30.

GATA4 and GATA5 are potential tumor suppressors and biomarkers in colorectal cancer.

Hellebrekers DM, Lentjes MH, van den Bosch SM, Melotte V, Wouters KA, Daenen KL, Smits KM, Akiyama Y, Yuasa Y, Sanduleanu S, Khalid-de Bakker CA, Jonkers D, Weijenberg MP, Louwagie J, van Criekinge W, Carvalho B, Meijer GA, Baylin SB, Herman JG, de Bruïne AP, van Engeland M.

Clin Cancer Res. 2009 Jun 15;15(12):3990-7. doi: 10.1158/1078-0432.CCR-09-0055. Epub 2009 Jun 9.

31.

Methylation of TFPI2 in stool DNA: a potential novel biomarker for the detection of colorectal cancer.

Glöckner SC, Dhir M, Yi JM, McGarvey KE, Van Neste L, Louwagie J, Chan TA, Kleeberger W, de Bruïne AP, Smits KM, Khalid-de Bakker CA, Jonkers DM, Stockbrügger RW, Meijer GA, Oort FA, Iacobuzio-Donahue C, Bierau K, Herman JG, Baylin SB, Van Engeland M, Schuebel KE, Ahuja N.

Cancer Res. 2009 Jun 1;69(11):4691-9. doi: 10.1158/0008-5472.CAN-08-0142. Epub 2009 May 12.

32.

Pharmacoepigenomics in colorectal cancer: a step forward in predicting prognosis and treatment response.

Smits KM, Cleven AH, Weijenberg MP, Hughes LA, Herman JG, de Bruïne AP, van Engeland M.

Pharmacogenomics. 2008 Dec;9(12):1903-16. doi: 10.2217/14622416.9.12.1903. Review.

PMID:
19072647
33.

The influence of 5-HTTLPR and STin2 polymorphisms in the serotonin transporter gene on treatment effect of selective serotonin reuptake inhibitors in depressive patients.

Smits KM, Smits LJ, Peeters FP, Schouten JS, Janssen RG, Smeets HJ, van Os J, Prins MH.

Psychiatr Genet. 2008 Aug;18(4):184-90. doi: 10.1097/YPG.0b013e3283050aca.

PMID:
18628680
34.

Genetic and epigenetic alterations in the von hippel-lindau gene: the influence on renal cancer prognosis.

Smits KM, Schouten LJ, van Dijk BA, Hulsbergen-van de Kaa CA, Wouters KA, Oosterwijk E, van Engeland M, van den Brandt PA.

Clin Cancer Res. 2008 Feb 1;14(3):782-7. doi: 10.1158/1078-0432.CCR-07-1753.

35.

Methodologic ramifications of paying attention to sex and gender differences in clinical research.

Prins MH, Smits KM, Smits LJ.

Gend Med. 2007;4 Suppl B:S106-10. Review.

PMID:
18156096
36.

Polymorphisms in genes related to activation or detoxification of carcinogens might interact with smoking to increase renal cancer risk: results from The Netherlands Cohort Study on diet and cancer.

Smits KM, Schouten LJ, van Dijk BA, van Houwelingen K, Hulsbergen-van de Kaa CA, Kiemeney LA, Goldbohm RA, Oosterwijk E, van den Brandt PA.

World J Urol. 2008 Feb;26(1):103-10. Epub 2007 Nov 3.

PMID:
17982751
37.
38.

Magnesium intake and colorectal cancer risk in the Netherlands Cohort Study.

van den Brandt PA, Smits KM, Goldbohm RA, Weijenberg MP.

Br J Cancer. 2007 Feb 12;96(3):510-3.

39.

A review on the design and reporting of studies on drug-gene interaction.

Smits KM, Schouten JS, Smits LJ, Stelma FF, Nelemans P, Prins MH.

J Clin Epidemiol. 2005 Jul;58(7):651-4. Epub 2005 Apr 18. Review.

PMID:
15939214
40.

Association of metabolic gene polymorphisms with tobacco consumption in healthy controls.

Smits KM, Benhamou S, Garte S, Weijenberg MP, Alamanos Y, Ambrosone C, Autrup H, Autrup JL, Baranova H, Bathum L, Boffetta P, Bouchardy C, Brockmoller J, Butkiewicz D, Cascorbi I, Clapper ML, Coutelle C, Daly AK, Muzi G, Dolzan V, Duzhak TG, Farker K, Golka K, Haugen A, Hein DW, Hildesheim A, Hirvonen A, Hsieh LL, Ingelman-Sundberg M, Kalina I, Kang D, Katoh T, Kihara M, Ono-Kihara M, Kim H, Kiyohara C, Kremers P, Lazarus P, Le Marchand L, Lechner MC, London S, Manni JJ, Maugard CM, Morgan GJ, Morita S, Nazar-Stewart V, Kristensen VN, Oda Y, Parl FF, Peters WH, Rannug A, Rebbeck T, Pinto LF, Risch A, Romkes M, Salagovic J, Schoket B, Seidegard J, Shields PG, Sim E, Sinnett D, Strange RC, Stucker I, Sugimura H, To-Figueras J, Vineis P, Yu MC, Zheng W, Pedotti P, Taioli E.

Int J Cancer. 2004 Jun 10;110(2):266-70.

41.

Influence of SERTPR and STin2 in the serotonin transporter gene on the effect of selective serotonin reuptake inhibitors in depression: a systematic review.

Smits KM, Smits LJ, Schouten JS, Stelma FF, Nelemans P, Prins MH.

Mol Psychiatry. 2004 May;9(5):433-41. Review.

PMID:
15037864
42.

Interaction between smoking, GSTM1 deletion and colorectal cancer: results from the GSEC study.

Smits KM, Gaspari L, Weijenberg MP, Dolzan V, Golka K, Roemer HC, Nedelcheva Kristensen V, Lechner MC, Mehling GI, Seidegard J, Strange RC, Taioli E.

Biomarkers. 2003 May-Aug;8(3-4):299-310.

PMID:
12944179
43.

K-ras oncogene mutations in sporadic colorectal cancer in The Netherlands Cohort Study.

Brink M, de Goeij AF, Weijenberg MP, Roemen GM, Lentjes MH, Pachen MM, Smits KM, de Bruïne AP, Goldbohm RA, van den Brandt PA.

Carcinogenesis. 2003 Apr;24(4):703-10.

PMID:
12727799
44.
45.

Preincubation of tumor cells with the anti-(MHC) class I antibody OX18 enhances tumor cell lysis by interleukin-2-activated NK cells.

Smits KM, Kuppen PJ, Eggermont AM, Fleuren GJ.

Transplant Proc. 1993 Oct;25(5):2806-7. No abstract available.

PMID:
8212242
46.

Major histocompatibility complex class I expression and sensitivity to interleukin-2 activated NK cell-mediated lysis of adenovirus-transformed baby rat kidney cells.

Smits KM, Kuppen PJ, Lazeroms SP, Eggermont AM, Fleuren GJ.

Transplant Proc. 1993 Oct;25(5):2804-5. No abstract available.

PMID:
8212241
47.

The development and purification of a bispecific antibody for lymphokine-activated killer cell targeting against the rat colon carcinoma CC531.

Kuppen PJ, Eggermont AM, Smits KM, van Eendenburg JD, Lazeroms SP, van de Velde CJ, Fleuren GJ.

Cancer Immunol Immunother. 1993 Jun;36(6):403-8.

PMID:
8500112

Supplemental Content

Loading ...
Support Center